相关实验视频

Updated: Jun 18, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

研究甲状腺功能下降症持续时间对听觉功能的影响:一项实验性动物研究

Arzu Tatlıpınar¹, Ahmet Kutluhan², Bülent Şerbetçioğlu³

¹Ear Nose Throat Clinic, Yeditepe University, Istanbul, Turkey.

The Annals of otology, rhinology, and laryngology

|December 10, 2025

概括

长期获得的甲状腺功能低下会对大鼠的听力功能和耳结构产生负面影响. 甲状腺功能低下的持续时间与听力障碍和耳损伤的严重程度直接相关.

科学领域:

耳鼻喉科耳鼻喉科耳鼻喉科
内分泌学在内分泌学.
实验医学是一种实验医学.

背景情况:

已知先天性甲状腺功能低下症会影响听力发育.
获得性甲状腺功能低下症对听力的影响,特别是其持续时间,还不清楚.
有限的数据存在于长期的甲状腺功能低下症和听力功能之间的关系.

研究的目的:

为了研究不同持续时间的实验性诱导甲状腺功能低下症对听觉功能的影响.
评估甲状腺功能低下对耳形态学的影响.
为了确定甲状腺功能低下的持续时间是否会影响听觉结果.

主要方法:

维斯塔尔白性大鼠被分为对照组和三组甲状腺功能低下组 (15,30,45天的6-n-propyl-2-thiouracil暴露).
听觉功能使用耳声发射 (OAE) 和听觉脑干响应 (ABR) 测试进行评估.
血清T4和TSH水平证实了甲状腺功能低下症,并对耳组织进行了本病理学检查.

主要成果:

与对照组相比,甲状腺下降大鼠在ABR测试中显示出明显增加的听觉值和延长的波延迟.
在甲状腺功能低下组中,耳声发射响应表现出降低的幅度.
组织病理学分析显示,在所有甲状腺下垂体组中,耳结构发生了显著的变化.

结论:

实验诱导的甲状腺功能低下会以持续时间依赖的方式对听觉功能产生不利影响.
甲状腺激素对于维持听觉生理学至关重要.
长期的甲状腺功能低下会导致功能和结构层面的逐渐听力损失.

关键词:

这就是ABR ABR.甲状腺 (cochlea) 是一种甲状腺功能低下症甲状腺功能低下症声波排放的排放声波排放的排放

更多相关视频

Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage

Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage

Published on: February 10, 2023

Cryosectioning and Immunostaining Mouse Inner Ear Tissue: From Embryonic to Adult Stages

Cryosectioning and Immunostaining Mouse Inner Ear Tissue: From Embryonic to Adult Stages

Published on: April 11, 2025

相关概念视频

Toxicity Testing in Animals

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

Hypothyroidism II: Pathophysiology

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...